762 related articles for article (PubMed ID: 10528221)
1. Photochemical treatment with S-59 psoralen and ultraviolet A light to control the fate of naive or primed T lymphocytes in vivo after allogeneic bone marrow transplantation.
Truitt RL; Johnson BD; Hanke C; Talib S; Hearst JE
J Immunol; 1999 Nov; 163(9):5145-56. PubMed ID: 10528221
[TBL] [Abstract][Full Text] [Related]
2. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
Johnson BD; Becker EE; Truitt RL
Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
[TBL] [Abstract][Full Text] [Related]
3. Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft-vs-host disease in mixed allogeneic chimeras (B10 + B10.D2----B10).
Ildstad ST; Wren SM; Bluestone JA; Barbieri SA; Stephany D; Sachs DH
J Immunol; 1986 Jan; 136(1):28-33. PubMed ID: 2933464
[TBL] [Abstract][Full Text] [Related]
4. Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow.
Truitt RL; Atasoylu AA
Bone Marrow Transplant; 1991 Jul; 8(1):51-8. PubMed ID: 1833016
[TBL] [Abstract][Full Text] [Related]
5. Abrogation of graft-vs.-leukemia activity after depletion of CD3+ T cells in a murine model of MHC-matched peripheral blood progenitor cell transplantation (PBPCT).
Uharek L; Glass B; Zeis M; Dreger P; Steinmann J; Löffler H; Schmitz N
Exp Hematol; 1998 Feb; 26(2):93-9. PubMed ID: 9472798
[TBL] [Abstract][Full Text] [Related]
6. Graft engineering using ex vivo methods to limit GVHD: fludarabine treatment generates superior GVL effects in allogeneic BMT.
Li JM; Giver CR; Waller EK
Exp Hematol; 2006 Jul; 34(7):895-904. PubMed ID: 16797417
[TBL] [Abstract][Full Text] [Related]
7. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
Johnson BD; Drobyski WR; Truitt RL
Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480
[TBL] [Abstract][Full Text] [Related]
8. Rapamycin promotes emergence of IL-10-secreting donor lymphocyte infusion-derived T cells without compromising their graft-versus-leukemia reactivity.
Durakovic N; Radojcic V; Powell J; Luznik L
Transplantation; 2007 Mar; 83(5):631-40. PubMed ID: 17353785
[TBL] [Abstract][Full Text] [Related]
9. Amotosalen-treated donor T cells have polyclonal antigen-specific long-term function without graft-versus-host disease after allogeneic bone marrow transplantation.
Hossain MS; Roback JD; Lezhava L; Hillyer CD; Waller EK
Biol Blood Marrow Transplant; 2005 Mar; 11(3):169-80. PubMed ID: 15744235
[TBL] [Abstract][Full Text] [Related]
10. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
Johnson BD; Becker EE; LaBelle JL; Truitt RL
J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
[TBL] [Abstract][Full Text] [Related]
11. Blockade of the CD40/CD154 pathway enhances T-cell-depleted allogeneic bone marrow engraftment under nonmyeloablative and irradiation-free conditioning therapy.
Pan Y; Luo B; Sozen H; Kalscheuer H; Blazar BR; Sutherland DE; Hering BJ; Guo Z
Transplantation; 2003 Jul; 76(1):216-24. PubMed ID: 12865813
[TBL] [Abstract][Full Text] [Related]
12. Abrogation of bone marrow allograft resistance in mice by increased total body irradiation correlates with eradication of host clonable T cells and alloreactive cytotoxic precursors.
Schwartz E; Lapidot T; Gozes D; Singer TS; Reisner Y
J Immunol; 1987 Jan; 138(2):460-5. PubMed ID: 3098843
[TBL] [Abstract][Full Text] [Related]
13. Use of anti-CD3 epsilon F(ab')2 fragments in vivo to modulate graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC-matched bone marrow transplantation.
Johnson BD; McCabe C; Hanke CA; Truitt RL
J Immunol; 1995 May; 154(10):5542-54. PubMed ID: 7730653
[TBL] [Abstract][Full Text] [Related]
14. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
Li JM; Gorechlad J; Larsen CP; Waller EK
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
[TBL] [Abstract][Full Text] [Related]
15. Characterization of alloimmunization-induced T lymphocytes reactive against AKR leukemia in vitro and correlation with graft-vs-leukemia activity in vivo.
Truitt RL; Shih CY; Lefever AV; Tempelis LD; Andreani M; Bortin MM
J Immunol; 1983 Oct; 131(4):2050-8. PubMed ID: 6194224
[TBL] [Abstract][Full Text] [Related]
16. The influence of graft-versus-host reactivity, lymphocyte depletion, and cell dose on allogeneic bone marrow engraftment.
Glass B; Uharek L; Gaska T; Gassmann W; Löffler H; Müller-Ruchholtz W
Bone Marrow Transplant; 1993; 12 Suppl 3():S41-7. PubMed ID: 8124257
[TBL] [Abstract][Full Text] [Related]
17. Ex vivo soluble fas ligand treatment of donor cells to selectively reduce murine acute graft versus host disease.
Georgantas RW; Bohana-Kashtan O; Civin CI
Transplantation; 2006 Aug; 82(4):471-8. PubMed ID: 16926590
[TBL] [Abstract][Full Text] [Related]
18. Differential sensitivity of T lymphocytes and hematopoietic precursor cells to photochemotherapy with 8-methoxypsoralen and ultraviolet A light.
Mabed M; Coffe C; Racadot E; Angonin R; Pavey JJ; Tiberghien P; Herve P
Ann Hematol; 2006 Jan; 85(1):17-24. PubMed ID: 16208471
[TBL] [Abstract][Full Text] [Related]
19. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
[TBL] [Abstract][Full Text] [Related]
20. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
Xia G; Truitt RL; Johnson BD
Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
